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Research
Research on polycyclic aromatic hydrocar-
bons (PAHs) and related halogenated aro-
matic hydrocarbons (HAHs) historically 
has focused on the ability of these common 
environmental contaminants to induce cell 
transformation. These contaminants also have 
been studied for their induction of a number 
of biological responses, including immuno-
toxicity. PAHs and HAHs reduce bone mar-
row and thymus cellularity, impair B- and 
T-lymphocyte proliferation, and alter B- and 
T-lymphocyte differentiation and function. 
The consequences of these alterations in 
immune system function include a decrease 
in pathogen and tumor immunity (Head and 
Lawrence 2009; Kerkvliet 2009) and poten-
tially a skewing of immune responses toward 
pathologic autoimmunity (Funatake et al. 
2005; Quintana et al. 2008; Veldhoen et al. 
2008). Many PAHs and HAHs bind to and 
activate the aryl hydrocarbon receptor (AhR), 
and their toxic effects require this activation 
(Fernandez-Salguero et al. 1996). The AhR 
activates transcription of multiple genes, such 
as those responsible for metabolism of PAHs 
and HAHs [e.g., cytochrome P450 (CYP) 
genes], and suppresses the transcription of 
others (e.g., immunoglobulin) (Denison et al. 
2002; Sulentic et al. 1998).
Hazard and risk assessment typically is 
determined for individual chemicals; however, 
human and wildlife exposures to environmen-
tal contaminants usually occur as mixtures. 
Human exposure to toxic AhR agonists fre-
quently is determined by measuring, in serum 
extracts, individual common polychlorinated 
biphenyl (PCB) or polychlorinated dibenzo-
p-dioxin/furan (PCDD/PCDF) congeners 
by high-resolution gas chromatography/mass 
spectrometry (GC/MS) and then calculat-
ing a total “toxic equivalence” (TEQ) based 
on the ability of each compound to induce 
toxic effects (the sum of the products of each 
compound’s concentration multiplied by 
its TEQ value) (Van den Berg et al. 2006). 
Two critical assumptions of this approach 
may influence the risk assessment of exposure 
to AhR agonist mixtures. This method does 
not account for a) the antagonistic behav-
ior of ortho-substituted PCBs (Harper et al. 
1995; Howard et al. 2007) or b) the agonis-
tic or antagonistic behavior and toxicity of 
nonchlorinated AhR ligands (Denison and 
Nagy 2003) (e.g., PAHs, indoles, and fla-
vonoids), all of which occur at much higher 
concentrations in the environment than 
do dioxin-like compounds (Safe 1998) and 
would be excluded by serum extraction.
One advance in the assessment of AhR 
ligand mixture exposure has been the use 
of AhR-dependent bioassays, such as the 
chemical-activated luciferase gene expression 
(CALUX) assay (Windal et al. 2005). The 
attraction of this approach lies in its poten-
tial to assess the cumulative biological effects 
of a mixture of extractable AhR ligands, 
whether the effect of an individual ligand is 
agonistic or antagonistic. Some studies have 
demonstrated a strong association between 
AhR activity, as measured in acid silica-col-
umn–processed serum extracts by CALUX, 
and TEQ calculated from GC/MS assess-
ment (r > 0.7) (Covaci et al. 2002; Pauwels 
et al. 2000; Van Den Heuvel et al. 2002). 
However, other studies report finding little 
or no correlation (r < 0.6), with a population-
dependent range of correlations determined in 
a single study (r = 0.43–0.73) (Koppen et al. 
2001; Porpora et al. 2009; Van Wouwe et al. 
2004; Warner et al. 2005). These differences 
could reflect the biological interaction of mul-
tiple full AhR agonists, partial agonists, and 
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Ba c k g r o u n d: Aryl hydrocarbon receptor (AhR) ligands adversely affect many biological processes. 
However, assessment of the significance of human exposures is hampered by an incomplete under-
standing of how complex mixtures affect AhR activation/inactivation.
oBjectives: These studies used biological readouts to provide a broader context for estimating 
human risk than that obtained with serum extraction and gas chromatography/mass spectroscopy 
(GC/MS)-based assays alone.
Me t h o d s : AhR agonist activity was quantified in sera from dioxin-treated mice, commercial 
human sources, and polychlorinated biphenyl (PCB)–exposed Faroe Islanders using an AhR-driven 
reporter cell line. To validate relationships between serum AhR agonist levels and biological out-
comes, AhR agonist activity in mouse sera correlated with toxic end points. AhR agonist activity in 
unmanipulated (“neat”) human sera was compared with these biologically relevant doses and with 
GC/MS-assayed PCB levels.
re s u l t s: Mouse serum AhR agonist activity correlated with injected dioxin dose, thymic atrophy, 
and heptomegaly, validating the use of neat serum to assess AhR agonist activity. AhR agonist activ-
ity in sera from Faroe Islanders varied widely, was associated with the frequency of recent pilot 
whale dinners, but did not correlate with levels of PCBs quantified by GC/MS. Surprisingly, sig-
nificant “baseline” AhR activity was found in commercial human sera.
co n c l u s i o n s: An AhR reporter assay revealed cumulative levels of AhR activation potential in neat 
serum, whereas extraction may preclude detection of important non-dioxin-like biological activity. 
Significant levels of AhR agonist activity in commercial sera and in Faroe Islander sera, compared 
with that from experimentally exposed mice, suggest human exposures that are biologically relevant 
in both populations.
key w o r d s : aryl hydrocarbon receptor, dioxin toxicity, Faroe Islands, human serum, immuno-
toxicity, polychlorinated biphenyl. Environ Health Perspect 118:693–698 (2010).  doi:10.1289/
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antagonists quantified in the CALUX assay 
but overlooked in the GC/MS assay.
Given the role that the AhR plays in critical 
physiologic functions and the potential limita-
tions in assessing the significance of exposures 
to contaminant mixtures, we propose that 
a broader perspective and a complementary 
biological approach be considered, specifically 
because the cumulative biological effects of 
agonists, partial agonists, and antagonists are 
impossible to predict from analytical assays. We 
hypothesize that adaptation of CALUX-like 
methods to use with whole, unmanipulated 
(“neat”) sera (Ziccardi et al. 2000) would avoid 
exclusion of some AhR agonists/antagonists by 
extraction of sera and would provide biologi-
cally relevant insights into the significance of 
human exposure to complex mixtures of AhR 
agonists and antagonists.
Materials and Methods
Animals and treatment. Animal stud-
ies were conducted in accordance with the 
Boston University Institutional Animal Care 
and Use Committee guidelines for humane 
treatment of animals and alleviation of suf-
fering. Female 5- to 7-week-old C57BL/6J 
mice were purchased from Jackson Laboratory 
(Bar Harbor, ME, USA). Six to 18 mice were 
dosed by intraperitoneal injection with vehicle 
(sesame oil) or 2,3,7,8-tetrachlorodibenzo-p-
dioxin (TCDD; 2.5, 5, 10, or 30 µg/kg; Ultra 
Scientific, North Kingstown, RI, USA). Eight 
days after treatment, blood was collected and 
pooled from two mice for each sample. The 
mice were euthanized, and the body weights 
were measured. Thymi and livers were resected 
and weighed. The number of viable thymo-
cytes was determined by trypan blue staining 
and counting using a hemocytometer.
Human sera. Approval of the protocol 
was obtained from the Faroese Ethical Review 
Committee and the Institutional Review 
Board at Harvard School of Public Health. 
Human subjects gave written informed con-
sent before the study. Blood samples were 
collected and sera prepared from pregnant 
women (gestational week 32) in 1994–1995 
(cohort 2) and in 2000–2001 (cohort 3) in 
the Faroe Islands. Dietary information was 
available from 149 and 211 women in each 
cohort, respectively. Serum samples were ana-
lyzed for the major PCB congeners by GC 
with electron-capture detection (Petersen et al. 
2006). The sum of PCBs was calculated as the 
sum of PCB-138, PCB-153, and PCB-180 
multiplied by 2 (Grandjean et al. 1995). The 
estimated dioxin-like activity of the major 
mono-ortho-PCBs was computed as the sum 
of PCB-105, PCB-118, and PCB-156, where 
the latter was weighted 5-fold higher accord-
ing to the World Health Organization TEQs 
(Van den Berg et al. 1998). The sum of PCBs 
and the estimated dioxin-like activity were 
highly correlated (r = 0.95).
All other human AB sera were purchased 
from commercial sources: SeraCare (Oceanside, 
CA, USA), ICN Biomedicals (Solon, OH, 
USA), Sigma (St. Louis, MO, USA), and 
Dynal (Invitrogen, Carlsbad, CA, USA). These 
sera were all collected in the United States.
Serum preparation. Serum was prepared 
by allowing the blood to clot and then remov-
ing the clot. Serum extractions and cleanup 
were performed as described previously (Murk 
et al. 1997) [see Supplemental Material 
(doi:10.1289/ehp.0901113)]. Activated char-
coal was used to remove non-ortho-substi-
tuted PCBs (Jensen and Sundtrom 1974) (see 
Supplemental Material). This method was 
validated to remove all AhR agonist activity 
in serum supplemented with 10–4 M Aroclor 
1242 (see Supplemental Material, Figure 1).
Assessment of AhR activity. H1G1.1c3 
cells were generously provided by M.S. 
Denison (University of California, Davis, CA, 
USA). Cells were maintained and prepared 
for experiments as described previously (Nagy 
et al. 2002), except that cells were plated at 
a concentration of 7.5 × 104 cells per well 
and sera were applied in 10-µL aliquots 
[see Supplemental Material (doi:10.1289/
ehp.0901113)]. In specificity experiments, 
wells were pretreated with either DMSO 
(0.5% final concentration) or the AhR antago-
nist CH223191 (10–5 M final concentration) 
(EMD Chemicals, San Diego, CA, USA). For 
calculation of serum AhR agonist activity, 
the standard curve was fitted using the four-
parameter sigmoid Hill equation. Triplicate 
fluorescence measurements for each serum 
sample were averaged and used to determine 
the serum AhR agonist activity, in picograms 
TCDD equivalents (eq) per milliliter, by 
interpolation from the fitted standard curve 
(see Supplemental Material, Figure 2).
Statistics. Data are reported as means ± SE. 
Linear and nonlinear (exponential) regres-
sion analyses (Sigma Plot; Systat Software, 
Chicago, IL, USA) were used where appropri-
ate to determine r and r2. Statistical analyses 
were performed with Statview (SAS Institute 
Inc., Cary, NC, USA). Student’s t-tests, the 
t-statistic, and one-factor analyses of variance 
(ANOVAs) combined with Dunnett’s test or 
the Tukey–Kramer multiple comparisons test 
were used to determine significance.
Results
Validation and calibration of a neat serum 
AhR agonist activity assay in a mouse model 
of TCDD toxicity. Exposure to AhR agonists 
results in receptor-dependent immunotoxic 
and hepatotoxic effects in animal models 
(Fernandez-Salguero et al. 1996). To validate 
the use of neat serum in a sensitive reporter 
assay for AhR activation and to calibrate the 
injected dose of TCDD with serum AhR 
agonist activity and toxic end points in vivo, 
C57BL/6 mice were dosed with vehicle or 
TCDD by intraperitoneal injection.
Mouse serum was applied directly to 
mouse hepatoma cells stably transfected with 
an AhR-driven enhanced green fluorescent 
protein (EGFP)-expressing reporter construct 
with a promoter similar to that in the AhR–
CALUX assay (Nagy et al. 2002). These assays 
have been shown to produce similar results, 
with the advantage that the EGFP provides 
a nondestructive readout (Nagy et al. 2002; 
Nording et al. 2007; Peters et al. 2006). We 
calculated AhR agonist activity values, pre-
sented as picograms TCDD equivalents (eq) 
per milliliter, by interpolation from TCDD 
standard curves. Although sometimes referred 
to as TEQs, this measure itself is not a meas-
ure of toxicity. We observed a significant 
increase in AhR agonist activity after injection 
of ≥ 5 µg/kg TCDD (Figure 1A). The increase 
was linear and highly correlated with the 
injected TCDD dose (Figure 1B). Although 
expected, these results rigorously demonstrate 
for the first time a linear relationship between 
AhR agonist exposure and TCDD equivalents 
measured in neat sera.
The thymus is an extremely sensitive 
TCDD target, with exposure resulting in AhR-
dependent thymic involution (Staples et al. 
1998). We observed statistically significant 
decreases in thymus:body weight ratios and 
Figure 1. TCDD injection results in biologically active serum TCDD concentrations, as determined in neat 
serum applied to H1G1.1c3 cells containing an AhR reporter. (A) Means ± SE from three to nine pools of 
sera. (B) Linear regression: r2 = 0.952; r = 0.976; p < 0.01.
*Significantly different from control, p < 0.05 (ANOVA, Dunnett’s test).
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total thymocyte number at a dose as low as 
2.5 µg TCDD/kg [see Supplemental Material, 
Figure 3 (doi:10.1289/ehp.0901113)]. 
Thymus:body weight ratios correlated inversely 
but nonlinearly with mouse serum AhR ago-
nist activity (Figure 2A). Similarly, liver:body 
weight ratios increased with dose of TCDD 
(see Supplemental Material, Figure 4) and cor-
related with mouse serum AhR agonist activity 
(Figure 2B). These in vivo results strongly sup-
port the hypothesis that AhR agonist activity, 
determined in neat serum samples, correlates 
with injected TCDD dose and toxicity.
Analysis of AhR agonist activity in neat sera 
from human populations. As part of an ongoing 
study on the effects of environmental contami-
nants on the immune system, blood samples 
were collected from two cohorts of pregnant 
women from the Faroe Islands. We evaluated 
sera from 156 cohort 2 donors (1994–1995) 
and from 227 cohort 3 donors (2000–2001). 
In this community, the traditional seafood 
diet includes pilot whale, the blubber of which 
contains elevated concentrations of persistent 
organic pollutants (Dam and Bloch 2000), 
which results in elevated exposures to PCBs, 
but not to PCDD/PCDFs (Grandjean et al. 
1995; Heilmann et al. 2006). Based on toxico-
logic evidence, the Faroese health authorities in 
1998 recommended that women of reproduc-
tive age should avoid eating whale.
For assessment of AhR agonist activity, 
we applied human sera to H1G1.1c3 cells 
as described for the mouse studies. Results 
from cohort 2 indicated a range of serum 
AhR agonist activity, with 24 samples (90th 
percentile) exhibiting ≥ 1.4 pg TCDD eq/mL 
(Figure 3A), the serum AhR agonist activity 
measured in mouse sera from TCDD-treated 
mice exhibiting thymic and hepatic toxic-
ity. Interestingly, the average AhR agonist 
activity in sera from cohort 2 (1.09 ± 0.02 pg 
TCDD eq/mL) was significantly higher than 
the AhR agonist activity in sera from vehicle-
treated mice (e.g., Figure 1; 0.65 ± 0.04 pg 
TCDD eq/mL; p < 0.01, Student’s t-test). 
Furthermore, we observed a significantly 
lower average level of AhR agonist activity in 
the sera of cohort 3 donors (Figure 3B) than 
in cohort 2 donors (1.09 ± 0.02 vs. 0.71 ± 
0.02 pg TCDD eq/mL; p < 0.01, Student’s 
t-test), with only individuals in the 97th per-
centile exhibiting serum AhR agonist activities 
≥ 1.4 pg TCDD eq/mL, suggesting a decrease 
in exposure to AhR agonists during the inter-
val between collection of samples from each 
cohort and after issuance of a health advisory 
concerning whale consumption.
In cohort 2, 54 women had no whale 
meals during pregnancy, 41 and 25 had one 
and two whale meals per month, respectively, 
and 29 were more frequent consumers. The 
AhR agonist activity did not differ among the 
first three groups and showed an overall aver-
age of 1.07 ± 0.03 pg TCDD eq/mL, whereas 
the average for high consumers was 1.18 ± 
0.06 pg TCDD eq/mL. In cohort 3, whale 
consumption was much less frequent. A total 
of 75 women had eaten no whale, 87 had up 
to three whale meals during the pregnancy, 
and 49 had eaten whale more frequently 
and up to once per week. The AhR agonist 
activity did not differ between the first two 
groups and showed an overall average of 0.69 
± 0.02 pg TCDD eq/mL, whereas the aver-
age for high consumers was 0.80 ± 0.07 pg 
TCDD eq/mL (p = 0.07, r = 0.13). If the 
nonconsumers were omitted, the correlation 
improved (r = 0.17, p = 0.04). For the com-
bined data from both cohorts, the correlation 
(r = 0.27) was highly significant (p < 0.001).
Because of this considerable range in serum 
AhR activity within and between the two 
Faroe Islands cohorts, and the apparently lower 
level of baseline AhR agonist activity in mouse 
compared with human sera, we examined the 
levels of “baseline” serum AhR agonist activity 
in sera from the general U.S. population. We 
determined AhR agonist activity in pools of 
human serum samples, each from one of four 
independent commercial sources, and com-
pared these with individual sera from Faroe 
Islanders previously shown to express the high-
est (upper 10%, 1.60 ± 0.05 pg TCDD eq/mL 
serum) or lowest (lower 10%, 0.30 ± 0.02 pg 
TCDD eq/mL serum) serum AhR agonist 
activity (e.g., Figure 3). Surprisingly, the four 
pools of commercial sera differed in their level 
of AhR agonist activity, varying from a low of 
0.50 ± 0.01 pg TCDD eq/mL serum (Dynal) 
to a high of 1.32 ± 0.02 pg TCDD eq/mL 
serum (SeraCare) (Figure 4). These results 
suggest that significant levels of AhR agonist 
activity in human populations are not uncom-
mon. It is unknown whether this background 
AhR agonist activity results from exposure to 
exogenous AhR ligands or to production of 
endogenous ligands.
Figure 2. TCDD treatment results in thymic atrophy (A) and hepatomegaly (B) that correlate with serum 
AhR agonist activity. Data are means ± SE from three to nine data points from organs grouped by serum 
pooling. Nonlinear regressions between serum AhR agonist activity and toxic end points: A, r2 = 0.964; 
r = 0.979; B, r 2 = 0.980; r = 0.990. 
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Having quantified the cumulative level 
of AhR agonist activity in sera from Faroe 
Islanders, we next evaluated whether the bio-
logical readout correlated with PCB exposure. 
Although elevated levels of PCBs have been 
found in this population (Grandjean et al. 
1995), we observed no significant relationship 
between summed PCB levels and Faroe serum 
AhR agonist activity determined in the bioas-
say [see Supplemental Material, Figure 5A 
(doi:10.1289/ehp.0901113)]. To determine 
whether serum extraction potentially influ-
enced the AhR agonist activity measured in 
the typical CALUX-like assay, we prepared 
serum extracts and compared the AhR ago-
nist activities in the Faroe serum extracts and 
in neat sera. Although we observed a slight 
upward trend in the comparison, we found 
minimal correlation between AhR agonist 
activity in the extract and in the neat Faroe 
sera (see Supplemental Material, Figure 5B). 
These data suggest that extraction and pro-
cessing procedures may alter the relative com-
position of AhR agonists and/or antagonists 
in sera, thereby influencing either a chemical 
or biological assessment of toxicity.
We examined the contribution of planar 
HAHs to the observed AhR agonist activity 
by depletion of these AhR agonists from sera 
by charcoal stripping (Jensen and Sundtrom 
1974). Samples from both Faroe Islands 
cohorts exhibiting the highest (10%) serum 
AhR agonist activity and the commercial 
human serum pools were treated with acti-
vated charcoal before assessment of serum 
AhR agonist activity. Charcoal treatment 
resulted in a significant, although incom-
plete, reduction in serum AhR agonist activity 
(Figure 5A). Next, we determined the effect 
of a pure AhR antagonist, CH223191 (Kim 
et al. 2006), on the ability of sera to induce 
reporter activity. H1G1.1c3 cells were pre-
treated either with vehicle or with CH223191 
before application of sera. CH223191 inhib-
ited serum AhR agonist activity in samples 
from cohort 2, cohort 3, and the four com-
mercial samples, although inhibition of 
activity in the Dynal serum failed to reach sta-
tistical significance (Figure 5B). Interestingly, 
CH223191 appeared to reduce the serum 
AhR agonist activity measured in human sera 
to a greater extent than did charcoal treat-
ment, and CH223191 significantly reduced 
the AhR agonist activity measured in char-
coal-treated serum (Figure 5C), confirming 
that the charcoal-resistant activity was AhR 
specific. Thus, we conclude that a significant 
fraction of AhR agonist activity found in both 
an HAH-exposed and the general U.S. popu-
lation is not removed by a standard procedure 
known to remove dioxin-like AhR ligands.
Discussion
Assessment of human exposure to toxic AhR 
ligands traditionally relies on GC/MS analysis 
of common PCB and PCDD/PCDF con-
geners extracted from serum. Although this 
method can specifically identify and quantify 
HAH congeners, estimating the toxicity of the 
exposure relies on extrapolation to the bio-
logical AhR-activating capacity of the mixture 
using the TEQ method (Van den Berg et al. 
2006). Furthermore, the estimation of toxic-
ity from a calculated TEQ relies on several 
assumptions: that the effect of all AhR ligands 
is positively additive, that all biologically rel-
evant chemicals are equally extractable from 
samples, and that AhR activation, regardless 
of the inducing agent, is a monolithic quanti-
tative event that always results in an outcome 
equivalent to that seen after activation with 
TCDD. Here, we demonstrate that caution 
should be taken with regard to at least some 
of these assumptions.
The central hypothesis driving these stud-
ies was that analysis of AhR agonist activity in 
neat serum, as a cumulative measure of AhR 
ligand (agonist, partial agonist, antagonist) 
exposure, would provide a broader context for 
interpretation of GC/MS-determined TEQs 
and exposure assessment. To begin to test 
the hypothesis, we determined the relation-
ship between controlled TCDD exposures 
and serum AhR agonist activity in a mouse 
model. Mouse serum AhR agonist activity 
linearly correlated with the injected TCDD 
dose, validating the use of neat sera to detect 
circulating AhR agonists.
We then extended studies of AhR activity 
to analyses of sera from a human population 
exposed to HAHs in the diet and analyses 
of commercially available human sera pools. 
Several characteristics of the data were of 
note. First, a range of serum AhR activity was 
measured in samples from the Faroe Islands 
population, suggesting that either pharma-
cokinetics or exposures to AhR agonists may 
differ within this population. Interestingly, 
the distribution of serum AhR agonist activ-
ity was higher in cohort 2 than in the more 
recent cohort 3, samples from which were 
collected after a dietary advisory to abstain 
from eating whale. Because the demographics 
of the participants in these two cohorts were 
similar, this decrease, and the association with 
the frequency of whale dinners during preg-
nancy, may reflect a decrease in whale blubber 
consumption. Additionally, this decrease may 
reflect a significant decrease in HAH emis-
sions and deposition over this time (Hays and 
Aylward 2003).
Second, “baseline” serum AhR agonist 
activity in the commercial serum pools, col-
lected from the U.S. population at large, dif-
fered considerably among sources for each 
serum pool. Additionally, two of the commer-
cial human sera (ICN and SeraCare) had sig-
nificantly greater serum AhR agonist activity 
than did sera from vehicle-treated mice, and 
their activity falls within the 70th and 90th 
percentile of Faroe cohorts 2 and 3, respec-
tively. Given the grain-based feed and short 
life span of the mice (i.e., limited AhR agonist 
exposure), it is tempting to speculate that the 
relatively high AhR agonist activity in some of 
Figure 5. Charcoal stripping or AhR antagonist cotreatment significantly reduces AhR activity induced by human serum: comparison of AhR agonist activity in 
neat and charcoal (ch)-treated sera (A), neat sera cotreated with vehicle or CH223191 (B), and charcoal-treated sera cotreated with vehicle or CH223191 (C; com-
mercial serum = ICN, Sigma, and SeraCare sera). Ch-treated, charcoal-treated. Data are presented as means ± SE of seven individual sera for the Faroe Island 
samples and three aliquots of each of the commercial sera.
*Significantly different from neat serum, p < 0.05 (Student’s t-test). **Significantly different from charcoal treated, p < 0.05 (ANOVA, Tukey–Kramer test).
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the commercial sera is atributable to accumu-
lated and ongoing exposures to environmental 
AhR ligand pollutants. Alternatively, exposure 
to PAHs and natural ligands found in plants 
could contribute to the total AhR activity 
measured in neat human serum. Recent stud-
ies have shown that the AhR-activating capac-
ity of extracted, but unprocessed, serum could 
be influenced significantly by consumption 
of a vegetable-based diet in humans (Connor 
et al. 2008; de Waard et al. 2008). For the 
Faroe Islanders, high AhR agonist activity 
could reflect exposure to natural AhR ligands 
found in whale blubber (Vetter et al. 2005). 
Also, endogenous, serum-borne ligands, such 
as bilirubin, biliverdin, and tryptophan metab-
olites (Denison and Nagy 2003), exhibit AhR 
agonist activity and could contribute to the 
high level of serum AhR activity in humans.
Third, AhR agonist activity measured in 
Faroe serum was not significantly correlated 
with summed PCB exposure and was partially 
resistant to charcoal treatment. Taken together, 
the data suggest that a significant portion of 
AhR agonist activity in the Faroe serum is 
not mediated by charcoal-absorbable, dioxin-
like, non-ortho-PCB congeners. Interestingly, 
comparison of PCB exposure and activity of 
CYP1A2, an enzyme whose expression is con-
trolled by AhR, in the Faroe Islands population 
also did not reveal a correlation (Petersen et al. 
2006). Previous studies have demonstrated 
that, whereas the CALUX assay–determined 
and the GC/MS-determined TEQs are highly 
correlated when only the PCDD/PCDF frac-
tion of serum is analyzed, the correlation dissi-
pates when the PCB fraction is included (Van 
Wouwe et al. 2004; Windal et al. 2005). Thus, 
the CALUX assay provides an accurate assess-
ment of PCDD/PCDF exposure only when 
the PCDD/PCDF fraction alone is used. This 
also is illustrated by the results shown here, 
with a highly significant correlation between 
mouse serum AhR activity and TCDD dose.
When the GC/MS-determined TEQs do 
not correspond to CALUX-determined AhR 
activities, the question then becomes, what 
added information is the CALUX assay indi-
cating about toxic potency? We demonstrate 
that mouse serum AhR activity correlates, in 
an asymptotic manner, with toxic end points 
(thymic atrophy and hepatomegaly) character-
istic of TCDD exposure. However, exposures 
tend to be complex, containing both agonis-
tic and antagonistic components. Analysis of 
PCDD/PCDF congeners alone would not 
take into account the potentially ameliorat-
ing effects of antagonistic compounds. AhR 
antagonists found in the diet or synthesized 
endogenously could negatively affect AhR 
activation. Natural products, including fla-
vonoids, catechins, curcumin, resveratrol, 
and lutein, all antagonize the AhR (Denison 
and Nagy 2003). In addition, Aroclors and 
ortho-substituted PCBs contain or are partial 
agonists that suppress TCDD-induced immu-
notoxicity, presumably through competitive 
binding to the AhR (Peters et al. 2006; Suh 
et al. 2003).
Finally, it has been argued that only chem-
icals that are dioxin-like in structure and lead 
to AhR-dependent acute toxicity (as opposed 
to CYP-mediated toxicity of PAHs) should 
be considered in toxic potency analyses (Van 
den Berg et al. 2006). Considering that as 
much as 98% of the total daily AhR agonist 
intake could be attributable to non-dioxin-like 
compounds (Safe 1998), we suggest that AhR-
dependent toxicity should not be defined by 
this conventional syndrome alone. Although 
some AhR agonists, such as PAHs, do not 
persist in biological systems like TCDD, they 
are highly toxic to a number of organ systems, 
including the immune (Mann et al. 1999), 
endocrine (Matikainen et al. 2002), and neu-
rologic systems (McCallister et al. 2008). 
Using the immune system as a model for non-
dioxin-like, AhR-mediated toxicity, recent 
studies demonstrated that AhR-activating 
tryptophan metabolites influence develop-
ment of T-cell subsets that control inflamma-
tion, autoimmunity, and tumor immunity 
(Quintana et al. 2008; Veldhoen et al. 2008). 
Thus, consideration of the potential for non-
dioxin-like AhR agonists to alter many physi-
ologic functions (i.e., “toxicity”) is warranted.
Conclusions
These studies demonstrate that a sensitive 
reporter assay can be adapted to detect the 
cumulative AhR agonist activity in neat mam-
malian sera. Within limits (e.g., considering 
species differences in AhR affinity), the mouse 
model provides a system with which to relate 
serum AhR agonist activities with toxicologic 
end points and could be used to investigate 
the relationship between these factors in mix-
ture exposures. The human studies here and 
elsewhere demonstrate the need for an assay 
that measures cumulative AhR activity with-
out the need to know a priori the likely com-
position of and interactions between AhR 
agonist and antagonist mixtures and without 
a possible bias imposed by evaluation of only 
extractable dioxin-like compounds. These 
results highlight the need to perform both 
standard chemical analyses and bioassays to 
evaluate human exposure to environmental 
AhR ligands and ultimately to estimate risk.
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